nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP17A1—seminiferous tubule of testis—hypothyroidism	0.0786	0.241	CbGeAlD
Metoclopramide—Cardio-respiratory arrest—Liothyronine—hypothyroidism	0.064	0.117	CcSEcCtD
Metoclopramide—Methaemoglobinaemia—Liotrix—hypothyroidism	0.0281	0.0514	CcSEcCtD
Metoclopramide—HTR4—adrenal cortex—hypothyroidism	0.0234	0.0716	CbGeAlD
Metoclopramide—Cardio-respiratory arrest—Liotrix—hypothyroidism	0.0231	0.0423	CcSEcCtD
Metoclopramide—Menstruation irregular—Dextrothyroxine—hypothyroidism	0.0203	0.0371	CcSEcCtD
Metoclopramide—Menstruation irregular—Levothyroxine—hypothyroidism	0.0203	0.0371	CcSEcCtD
Metoclopramide—HTR4—pituitary gland—hypothyroidism	0.0189	0.0578	CbGeAlD
Metoclopramide—Cardiac failure congestive—Liothyronine—hypothyroidism	0.0183	0.0335	CcSEcCtD
Metoclopramide—HTR4—adrenal gland—hypothyroidism	0.0169	0.0517	CbGeAlD
Metoclopramide—HTR3A—nerve—hypothyroidism	0.0164	0.0503	CbGeAlD
Metoclopramide—Menstruation irregular—Liotrix—hypothyroidism	0.0149	0.0273	CcSEcCtD
Metoclopramide—CYP11B2—adrenal cortex—hypothyroidism	0.0132	0.0403	CbGeAlD
Metoclopramide—CYP11B1—adrenal cortex—hypothyroidism	0.0132	0.0403	CbGeAlD
Metoclopramide—CYP11B2—heart—hypothyroidism	0.0127	0.039	CbGeAlD
Metoclopramide—CYP11B2—cardiovascular system—hypothyroidism	0.012	0.0368	CbGeAlD
Metoclopramide—Wheezing—Levothyroxine—hypothyroidism	0.0109	0.0199	CcSEcCtD
Metoclopramide—Wheezing—Dextrothyroxine—hypothyroidism	0.0109	0.0199	CcSEcCtD
Metoclopramide—DRD2—nerve—hypothyroidism	0.0101	0.0308	CbGeAlD
Metoclopramide—CYP11B2—adrenal gland—hypothyroidism	0.0095	0.0291	CbGeAlD
Metoclopramide—CYP11B1—adrenal gland—hypothyroidism	0.0095	0.0291	CbGeAlD
Metoclopramide—CYP11B2—blood—hypothyroidism	0.0095	0.0291	CbGeAlD
Metoclopramide—CYP11B1—blood—hypothyroidism	0.0095	0.0291	CbGeAlD
Metoclopramide—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.00899	0.0164	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.00899	0.0164	CcSEcCtD
Metoclopramide—CYP2D6—urine—hypothyroidism	0.00875	0.0268	CbGeAlD
Metoclopramide—Hypertension—Liothyronine—hypothyroidism	0.00863	0.0158	CcSEcCtD
Metoclopramide—CYP17A1—adrenal cortex—hypothyroidism	0.00804	0.0246	CbGeAlD
Metoclopramide—Wheezing—Liotrix—hypothyroidism	0.00802	0.0147	CcSEcCtD
Metoclopramide—Tachycardia—Liothyronine—hypothyroidism	0.00796	0.0146	CcSEcCtD
Metoclopramide—CYP11B2—Glucocorticoid biosynthesis—POMC—hypothyroidism	0.00789	0.0624	CbGpPWpGaD
Metoclopramide—Fluid retention—Liotrix—hypothyroidism	0.00784	0.0143	CcSEcCtD
Metoclopramide—Cardiac arrest—Levothyroxine—hypothyroidism	0.00775	0.0142	CcSEcCtD
Metoclopramide—Cardiac arrest—Dextrothyroxine—hypothyroidism	0.00775	0.0142	CcSEcCtD
Metoclopramide—Hypotension—Liothyronine—hypothyroidism	0.00762	0.0139	CcSEcCtD
Metoclopramide—CYP11B1—Glucocorticoid biosynthesis—POMC—hypothyroidism	0.0068	0.0538	CbGpPWpGaD
Metoclopramide—CYP17A1—gonad—hypothyroidism	0.00666	0.0204	CbGeAlD
Metoclopramide—Cardiac failure congestive—Liotrix—hypothyroidism	0.00661	0.0121	CcSEcCtD
Metoclopramide—Body temperature increased—Liothyronine—hypothyroidism	0.00645	0.0118	CcSEcCtD
Metoclopramide—CYP17A1—Glucocorticoid biosynthesis—POMC—hypothyroidism	0.00636	0.0503	CbGpPWpGaD
Metoclopramide—Renal impairment—Liotrix—hypothyroidism	0.0063	0.0115	CcSEcCtD
Metoclopramide—CYP17A1—adrenal gland—hypothyroidism	0.0058	0.0178	CbGeAlD
Metoclopramide—Cardiac arrest—Liotrix—hypothyroidism	0.0057	0.0104	CcSEcCtD
Metoclopramide—CYP17A1—thyroid gland—hypothyroidism	0.0056	0.0171	CbGeAlD
Metoclopramide—CYP17A1—female gonad—hypothyroidism	0.00541	0.0166	CbGeAlD
Metoclopramide—Flushing—Levothyroxine—hypothyroidism	0.00523	0.00957	CcSEcCtD
Metoclopramide—Flushing—Dextrothyroxine—hypothyroidism	0.00523	0.00957	CcSEcCtD
Metoclopramide—Bronchospasm—Liotrix—hypothyroidism	0.0051	0.00932	CcSEcCtD
Metoclopramide—CYP17A1—Androgen biosynthesis—POMC—hypothyroidism	0.00493	0.039	CbGpPWpGaD
Metoclopramide—CYP17A1—testis—hypothyroidism	0.0048	0.0147	CbGeAlD
Metoclopramide—Nervousness—Dextrothyroxine—hypothyroidism	0.00477	0.00872	CcSEcCtD
Metoclopramide—Nervousness—Levothyroxine—hypothyroidism	0.00477	0.00872	CcSEcCtD
Metoclopramide—Tremor—Levothyroxine—hypothyroidism	0.0046	0.00841	CcSEcCtD
Metoclopramide—Tremor—Dextrothyroxine—hypothyroidism	0.0046	0.00841	CcSEcCtD
Metoclopramide—HTR3A—blood—hypothyroidism	0.00455	0.0139	CbGeAlD
Metoclopramide—CYP17A1—liver—hypothyroidism	0.00454	0.0139	CbGeAlD
Metoclopramide—Agitation—Dextrothyroxine—hypothyroidism	0.00451	0.00825	CcSEcCtD
Metoclopramide—Agitation—Levothyroxine—hypothyroidism	0.00451	0.00825	CcSEcCtD
Metoclopramide—Angioedema—Levothyroxine—hypothyroidism	0.00449	0.0082	CcSEcCtD
Metoclopramide—Angioedema—Dextrothyroxine—hypothyroidism	0.00449	0.0082	CcSEcCtD
Metoclopramide—CHRM1—cardiovascular system—hypothyroidism	0.00437	0.0134	CbGeAlD
Metoclopramide—Palpitations—Dextrothyroxine—hypothyroidism	0.00434	0.00793	CcSEcCtD
Metoclopramide—Palpitations—Levothyroxine—hypothyroidism	0.00434	0.00793	CcSEcCtD
Metoclopramide—Convulsion—Levothyroxine—hypothyroidism	0.00425	0.00778	CcSEcCtD
Metoclopramide—Convulsion—Dextrothyroxine—hypothyroidism	0.00425	0.00778	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00421	0.0333	CbGpPWpGaD
Metoclopramide—Anxiety—Levothyroxine—hypothyroidism	0.00417	0.00761	CcSEcCtD
Metoclopramide—Anxiety—Dextrothyroxine—hypothyroidism	0.00417	0.00761	CcSEcCtD
Metoclopramide—Confusional state—Dextrothyroxine—hypothyroidism	0.00404	0.00739	CcSEcCtD
Metoclopramide—Confusional state—Levothyroxine—hypothyroidism	0.00404	0.00739	CcSEcCtD
Metoclopramide—Tachycardia—Levothyroxine—hypothyroidism	0.00391	0.00715	CcSEcCtD
Metoclopramide—Tachycardia—Dextrothyroxine—hypothyroidism	0.00391	0.00715	CcSEcCtD
Metoclopramide—Flushing—Liotrix—hypothyroidism	0.00385	0.00704	CcSEcCtD
Metoclopramide—Insomnia—Levothyroxine—hypothyroidism	0.00362	0.00663	CcSEcCtD
Metoclopramide—Insomnia—Dextrothyroxine—hypothyroidism	0.00362	0.00663	CcSEcCtD
Metoclopramide—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00357	0.00653	CcSEcCtD
Metoclopramide—Dyspnoea—Levothyroxine—hypothyroidism	0.00357	0.00653	CcSEcCtD
Metoclopramide—Nervousness—Liotrix—hypothyroidism	0.00351	0.00641	CcSEcCtD
Metoclopramide—Fatigue—Dextrothyroxine—hypothyroidism	0.00345	0.00632	CcSEcCtD
Metoclopramide—Fatigue—Levothyroxine—hypothyroidism	0.00345	0.00632	CcSEcCtD
Metoclopramide—CYP11B2—Endogenous sterols—POMC—hypothyroidism	0.00339	0.0268	CbGpPWpGaD
Metoclopramide—Tremor—Liotrix—hypothyroidism	0.00338	0.00619	CcSEcCtD
Metoclopramide—Agitation—Liotrix—hypothyroidism	0.00332	0.00607	CcSEcCtD
Metoclopramide—Feeling abnormal—Levothyroxine—hypothyroidism	0.0033	0.00604	CcSEcCtD
Metoclopramide—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.0033	0.00604	CcSEcCtD
Metoclopramide—Angioedema—Liotrix—hypothyroidism	0.0033	0.00603	CcSEcCtD
Metoclopramide—Palpitations—Liotrix—hypothyroidism	0.00319	0.00583	CcSEcCtD
Metoclopramide—Urticaria—Dextrothyroxine—hypothyroidism	0.00318	0.00582	CcSEcCtD
Metoclopramide—Urticaria—Levothyroxine—hypothyroidism	0.00318	0.00582	CcSEcCtD
Metoclopramide—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00317	0.00579	CcSEcCtD
Metoclopramide—Body temperature increased—Levothyroxine—hypothyroidism	0.00317	0.00579	CcSEcCtD
Metoclopramide—Convulsion—Liotrix—hypothyroidism	0.00313	0.00572	CcSEcCtD
Metoclopramide—DRD2—pituitary gland—hypothyroidism	0.00312	0.00955	CbGeAlD
Metoclopramide—Hypertension—Liotrix—hypothyroidism	0.00312	0.0057	CcSEcCtD
Metoclopramide—Anxiety—Liotrix—hypothyroidism	0.00306	0.0056	CcSEcCtD
Metoclopramide—HTR4—G alpha (s) signalling events—TSHB—hypothyroidism	0.00301	0.0238	CbGpPWpGaD
Metoclopramide—HTR4—G alpha (s) signalling events—TSHR—hypothyroidism	0.00301	0.0238	CbGpPWpGaD
Metoclopramide—Confusional state—Liotrix—hypothyroidism	0.00297	0.00543	CcSEcCtD
Metoclopramide—Oedema—Liotrix—hypothyroidism	0.00295	0.00539	CcSEcCtD
Metoclopramide—CYP11B1—Endogenous sterols—POMC—hypothyroidism	0.00292	0.0231	CbGpPWpGaD
Metoclopramide—Tachycardia—Liotrix—hypothyroidism	0.00288	0.00526	CcSEcCtD
Metoclopramide—Asthenia—Levothyroxine—hypothyroidism	0.00287	0.00526	CcSEcCtD
Metoclopramide—Asthenia—Dextrothyroxine—hypothyroidism	0.00287	0.00526	CcSEcCtD
Metoclopramide—Hypotension—Liotrix—hypothyroidism	0.00275	0.00503	CcSEcCtD
Metoclopramide—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00274	0.00501	CcSEcCtD
Metoclopramide—Diarrhoea—Levothyroxine—hypothyroidism	0.00274	0.00501	CcSEcCtD
Metoclopramide—CYP17A1—Endogenous sterols—POMC—hypothyroidism	0.00273	0.0216	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.00271	0.0214	CbGpPWpGaD
Metoclopramide—Insomnia—Liotrix—hypothyroidism	0.00267	0.00487	CcSEcCtD
Metoclopramide—Dyspnoea—Liotrix—hypothyroidism	0.00263	0.0048	CcSEcCtD
Metoclopramide—Fatigue—Liotrix—hypothyroidism	0.00254	0.00465	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism of steroid hormones and vitamin D—POMC—hypothyroidism	0.00254	0.0201	CbGpPWpGaD
Metoclopramide—Rash—Dextrothyroxine—hypothyroidism	0.00253	0.00462	CcSEcCtD
Metoclopramide—Rash—Levothyroxine—hypothyroidism	0.00253	0.00462	CcSEcCtD
Metoclopramide—Dermatitis—Levothyroxine—hypothyroidism	0.00252	0.00461	CcSEcCtD
Metoclopramide—Dermatitis—Dextrothyroxine—hypothyroidism	0.00252	0.00461	CcSEcCtD
Metoclopramide—Headache—Levothyroxine—hypothyroidism	0.00251	0.00459	CcSEcCtD
Metoclopramide—Headache—Dextrothyroxine—hypothyroidism	0.00251	0.00459	CcSEcCtD
Metoclopramide—Feeling abnormal—Liotrix—hypothyroidism	0.00243	0.00444	CcSEcCtD
Metoclopramide—Nausea—Dextrothyroxine—hypothyroidism	0.00238	0.00435	CcSEcCtD
Metoclopramide—Nausea—Levothyroxine—hypothyroidism	0.00238	0.00435	CcSEcCtD
Metoclopramide—Urticaria—Liotrix—hypothyroidism	0.00234	0.00428	CcSEcCtD
Metoclopramide—Body temperature increased—Liotrix—hypothyroidism	0.00233	0.00426	CcSEcCtD
Metoclopramide—DRD2—testis—hypothyroidism	0.0023	0.00706	CbGeAlD
Metoclopramide—CYP11B1—Metabolism of steroid hormones and vitamin D—POMC—hypothyroidism	0.00219	0.0173	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Liotrix—hypothyroidism	0.00217	0.00397	CcSEcCtD
Metoclopramide—DRD2—cerebellum—hypothyroidism	0.00213	0.00652	CbGeAlD
Metoclopramide—Asthenia—Liotrix—hypothyroidism	0.00211	0.00387	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism of steroid hormones and vitamin D—POMC—hypothyroidism	0.00205	0.0162	CbGpPWpGaD
Metoclopramide—Diarrhoea—Liotrix—hypothyroidism	0.00202	0.00369	CcSEcCtD
Metoclopramide—Dizziness—Liotrix—hypothyroidism	0.00195	0.00356	CcSEcCtD
Metoclopramide—Rash—Liotrix—hypothyroidism	0.00186	0.0034	CcSEcCtD
Metoclopramide—Dermatitis—Liotrix—hypothyroidism	0.00186	0.00339	CcSEcCtD
Metoclopramide—Headache—Liotrix—hypothyroidism	0.00185	0.00338	CcSEcCtD
Metoclopramide—HTR4—G alpha (s) signalling events—AVP—hypothyroidism	0.00177	0.014	CbGpPWpGaD
Metoclopramide—Nausea—Liotrix—hypothyroidism	0.00175	0.0032	CcSEcCtD
Metoclopramide—CYP2D6—blood—hypothyroidism	0.00167	0.00513	CbGeAlD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00161	0.0127	CbGpPWpGaD
Metoclopramide—CYP11B2—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.00157	0.0125	CbGpPWpGaD
Metoclopramide—CYP2D6—female gonad—hypothyroidism	0.00156	0.00478	CbGeAlD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.00143	0.0113	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.00143	0.0113	CbGpPWpGaD
Metoclopramide—CYP2D6—testis—hypothyroidism	0.00138	0.00424	CbGeAlD
Metoclopramide—CYP11B1—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.00136	0.0107	CbGpPWpGaD
Metoclopramide—CYP2D6—liver—hypothyroidism	0.00131	0.00401	CbGeAlD
Metoclopramide—CYP2D6—cerebellum—hypothyroidism	0.00128	0.00392	CbGeAlD
Metoclopramide—CYP11B2—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00128	0.0101	CbGpPWpGaD
Metoclopramide—CYP17A1—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.00127	0.01	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—TRH—hypothyroidism	0.00123	0.00969	CbGpPWpGaD
Metoclopramide—HTR4—G alpha (s) signalling events—POMC—hypothyroidism	0.00118	0.00932	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.00116	0.00916	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—NKX2-1—hypothyroidism	0.00116	0.00916	CbGpPWpGaD
Metoclopramide—CYP11B1—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.0011	0.0087	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—TSHB—hypothyroidism	0.00109	0.00864	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—TSHR—hypothyroidism	0.00109	0.00864	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.00108	0.00854	CbGpPWpGaD
Metoclopramide—CYP17A1—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00103	0.00814	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—POMC—hypothyroidism	0.000964	0.00762	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.00096	0.00759	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—NKX2-1—hypothyroidism	0.000886	0.00701	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—NKX2-1—hypothyroidism	0.000867	0.00686	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000845	0.00668	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—IYD—hypothyroidism	0.0008	0.00633	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—TRH—hypothyroidism	0.000692	0.00548	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—IYD—hypothyroidism	0.000689	0.00545	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ATP5O—hypothyroidism	0.00068	0.00538	CbGpPWpGaD
Metoclopramide—CYP11B2—Biological oxidations—POMC—hypothyroidism	0.000678	0.00536	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—TRH—hypothyroidism	0.000664	0.00525	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—IYD—hypothyroidism	0.000645	0.0051	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—AVP—hypothyroidism	0.000644	0.00509	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TPO—hypothyroidism	0.000639	0.00506	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—PIK3C2A—hypothyroidism	0.000633	0.00501	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—TRH—hypothyroidism	0.000629	0.00497	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—TSHB—hypothyroidism	0.000617	0.00488	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—TSHR—hypothyroidism	0.000617	0.00488	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000594	0.0047	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000592	0.00469	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000588	0.00465	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ATP5O—hypothyroidism	0.000586	0.00463	CbGpPWpGaD
Metoclopramide—CYP11B1—Biological oxidations—POMC—hypothyroidism	0.000584	0.00462	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000562	0.00444	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—TSHB—hypothyroidism	0.00056	0.00443	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—TSHR—hypothyroidism	0.00056	0.00443	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TPO—hypothyroidism	0.000551	0.00436	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ATP5O—hypothyroidism	0.000548	0.00434	CbGpPWpGaD
Metoclopramide—CYP17A1—Biological oxidations—POMC—hypothyroidism	0.000546	0.00432	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000524	0.00414	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000524	0.00414	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TPO—hypothyroidism	0.000515	0.00408	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000511	0.00404	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000478	0.00378	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000463	0.00366	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00045	0.00356	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—TRH—hypothyroidism	0.000447	0.00354	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00044	0.00348	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—AVP—hypothyroidism	0.00044	0.00348	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CLTC—hypothyroidism	0.00043	0.0034	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—POMC—hypothyroidism	0.000428	0.00338	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000401	0.00317	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000401	0.00317	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—TSHB—hypothyroidism	0.000399	0.00315	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—TSHR—hypothyroidism	0.000399	0.00315	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000392	0.0031	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000392	0.0031	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—VAV3—hypothyroidism	0.000377	0.00299	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TRH—hypothyroidism	0.000371	0.00294	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000365	0.00288	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AVP—hypothyroidism	0.000364	0.00288	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—AVP—hypothyroidism	0.000349	0.00276	CbGpPWpGaD
Metoclopramide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000343	0.00271	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—VAV3—hypothyroidism	0.000343	0.00271	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—TRH—hypothyroidism	0.000342	0.00271	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—AVP—hypothyroidism	0.000337	0.00266	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—TRH—hypothyroidism	0.000335	0.00265	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TSHR—hypothyroidism	0.000331	0.00262	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TSHB—hypothyroidism	0.000331	0.00262	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AVP—hypothyroidism	0.00033	0.00261	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—AVP—hypothyroidism	0.000329	0.0026	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000312	0.00247	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000309	0.00244	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—TSHB—hypothyroidism	0.000305	0.00241	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—TSHR—hypothyroidism	0.000305	0.00241	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—TSHB—hypothyroidism	0.000299	0.00236	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—TSHR—hypothyroidism	0.000299	0.00236	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TSHB—hypothyroidism	0.000296	0.00234	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SH2B3—hypothyroidism	0.000295	0.00233	CbGpPWpGaD
Metoclopramide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000278	0.0022	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3C2A—hypothyroidism	0.000264	0.00209	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	0.00026	0.00206	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—POMC—hypothyroidism	0.000258	0.00204	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TSHB—hypothyroidism	0.000255	0.00202	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—TRH—hypothyroidism	0.000253	0.002	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—POMC—hypothyroidism	0.000242	0.00191	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TSHB—hypothyroidism	0.000239	0.00189	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000236	0.00187	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—AVP—hypothyroidism	0.000235	0.00186	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000231	0.00183	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—TRH—hypothyroidism	0.00023	0.00182	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3C2A—hypothyroidism	0.000227	0.0018	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—TSHB—hypothyroidism	0.000225	0.00178	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—TSHR—hypothyroidism	0.000225	0.00178	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	0.000224	0.00177	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—SLC5A5—hypothyroidism	0.000222	0.00175	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—POMC—hypothyroidism	0.000219	0.00174	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PRL—hypothyroidism	0.000219	0.00173	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3C2A—hypothyroidism	0.000213	0.00168	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	0.00021	0.00166	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000205	0.00162	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—TSHB—hypothyroidism	0.000205	0.00162	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—TSHR—hypothyroidism	0.000205	0.00162	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VAV3—hypothyroidism	0.000203	0.0016	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—POMC—hypothyroidism	0.000197	0.00156	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AVP—hypothyroidism	0.000195	0.00154	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—TRH—hypothyroidism	0.000193	0.00153	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—SLC5A5—hypothyroidism	0.000191	0.00151	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—TRH—hypothyroidism	0.000189	0.0015	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—AVP—hypothyroidism	0.00018	0.00142	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—SLC5A5—hypothyroidism	0.000179	0.00141	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—AVP—hypothyroidism	0.000176	0.00139	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—TRH—hypothyroidism	0.000176	0.00139	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—IYD—hypothyroidism	0.000174	0.00138	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—TSHB—hypothyroidism	0.000172	0.00136	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—TSHR—hypothyroidism	0.000172	0.00136	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—TRH—hypothyroidism	0.000172	0.00136	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—TSHB—hypothyroidism	0.000169	0.00133	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—TSHR—hypothyroidism	0.000169	0.00133	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000157	0.00124	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CLTC—hypothyroidism	0.000157	0.00124	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—TSHB—hypothyroidism	0.000157	0.00124	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—TSHR—hypothyroidism	0.000157	0.00124	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—POMC—hypothyroidism	0.000156	0.00124	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000154	0.00121	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—TSHB—hypothyroidism	0.000153	0.00121	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—TSHR—hypothyroidism	0.000153	0.00121	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ATP5O—hypothyroidism	0.000148	0.00117	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—POMC—hypothyroidism	0.000148	0.00117	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TPO—hypothyroidism	0.000139	0.0011	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—VAV3—hypothyroidism	0.000138	0.00109	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TRH—hypothyroidism	0.000136	0.00107	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AVP—hypothyroidism	0.000133	0.00105	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—POMC—hypothyroidism	0.00013	0.00103	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—VAV3—hypothyroidism	0.000125	0.00099	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IGF1—hypothyroidism	0.000125	0.000986	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TSHB—hypothyroidism	0.000121	0.000956	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TSHR—hypothyroidism	0.000121	0.000956	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AVP—hypothyroidism	0.000121	0.000954	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CLTC—hypothyroidism	0.00012	0.00095	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—POMC—hypothyroidism	0.00012	0.000945	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CLTC—hypothyroidism	0.000118	0.000929	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—POMC—hypothyroidism	0.000117	0.000925	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—POMC—hypothyroidism	0.000116	0.000917	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SH2B3—hypothyroidism	0.000108	0.000852	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—VAV3—hypothyroidism	0.000105	0.000834	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TRH—hypothyroidism	0.000104	0.000821	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—VAV3—hypothyroidism	0.000103	0.000816	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AVP—hypothyroidism	0.000102	0.000804	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TRH—hypothyroidism	0.000102	0.000803	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—POMC—hypothyroidism	9.99e-05	0.00079	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AVP—hypothyroidism	9.95e-05	0.000787	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—VAV3—hypothyroidism	9.58e-05	0.000757	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—VAV3—hypothyroidism	9.37e-05	0.000741	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—POMC—hypothyroidism	9.35e-05	0.000739	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TSHB—hypothyroidism	9.25e-05	0.000732	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TSHR—hypothyroidism	9.25e-05	0.000732	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AVP—hypothyroidism	9.23e-05	0.00073	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TSHB—hypothyroidism	9.05e-05	0.000716	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TSHR—hypothyroidism	9.05e-05	0.000716	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AVP—hypothyroidism	9.03e-05	0.000714	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—POMC—hypothyroidism	8.83e-05	0.000698	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SH2B3—hypothyroidism	8.24e-05	0.000652	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SH2B3—hypothyroidism	8.07e-05	0.000638	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—POMC—hypothyroidism	8.01e-05	0.000634	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PRL—hypothyroidism	7.99e-05	0.000632	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VAV3—hypothyroidism	7.4e-05	0.000585	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AVP—hypothyroidism	7.12e-05	0.000563	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—POMC—hypothyroidism	6.75e-05	0.000534	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—POMC—hypothyroidism	6.61e-05	0.000523	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TSHB—hypothyroidism	6.45e-05	0.00051	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—POMC—hypothyroidism	6.13e-05	0.000485	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PRL—hypothyroidism	6.12e-05	0.000484	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—POMC—hypothyroidism	6e-05	0.000475	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PRL—hypothyroidism	5.99e-05	0.000473	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	5.75e-05	0.000455	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VAV3—hypothyroidism	5.66e-05	0.000447	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VAV3—hypothyroidism	5.54e-05	0.000438	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AVP—hypothyroidism	5.45e-05	0.000431	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AVP—hypothyroidism	5.34e-05	0.000422	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC5A5—hypothyroidism	4.83e-05	0.000382	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—POMC—hypothyroidism	4.73e-05	0.000374	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—hypothyroidism	4.55e-05	0.00036	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—POMC—hypothyroidism	3.62e-05	0.000286	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—POMC—hypothyroidism	3.55e-05	0.00028	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—hypothyroidism	3.48e-05	0.000276	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—hypothyroidism	3.41e-05	0.00027	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—POMC—hypothyroidism	2.53e-05	0.0002	CbGpPWpGaD
